Abstract Library

#3724 Tackling drug activity and resistance mechanisms in neuroendocrine tumors treated with cabozantinib

Introduction: Neuroendocrine tumors (NETs) are highly vascularized malignancies and angiogenesis plays a relevant role in cell proliferation and survival. Nowadays, innovative therapies have amplified the paradigm treatment of NETs. Among the compounds with anti-vascular properties, cabozantinib (CAB) appeared promising.

Conference:

Presenting Author: Cella C

Authors: Cella C, Cazzoli R, Fazio N, de Petro G, Gaudenzi G,

Keywords: Neuroendocrine tumor, angiogenesis, zebrafish model, mouse model.,

#3630 Metformin suppresses small intestinal neuroendocrine tumor growth in vivo

Introduction: Small intestinal neuroendocrine tumors (SI-NETs) are rare and slow growing, but most patients are diagnosed at a late stage with distance metastases. In the past few years, several studies have reported the anti-tumor activity of metformin in different cancers, and recently we showed that metformin treatment repressed cell viability of SI-NET cells and inhibited the growth of GOT1 spheroids.

Conference:

Presenting Author:

Authors: Barazeghi E, Axling F, Hellman P, Norlén O, Stålberg P,

Keywords: neuroendocrine tumor, metformin, SI-NET xenograft,

#3536 Comparison of drug sensitivity profiles of various NEN spheroids

Introduction: Neuroendocrine neoplasms (NENs) are rare cancers that arise from neuroendocrine cells. NENs are classified as well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Small bowel and pancreatic NETs (SBNET & PNETs) are generally slow-growing but commonly metastasize to the liver and become aggressive cancers. Little is known about the drug sensitivity profile of these 3 NENs due to the lack of cellular and animal models of these malignancies. Recently, we have developed a protocol to culture NEN cells from patient tumors as patient-derived spheroids (PDS) and showed expression of NEN markers. The rarity and slow growing features of these spheroids have been hindering drug screens with many compounds.

Conference:

Presenting Author: Ear P

Authors: Tran C, Luis B, Sherman S, Mudd J, Abusada E,

Keywords: NET, NEC, spheroid, drug screening, PDX model,

#2834 Tumor-Promoting Effects of the Transcriptional Regulator CUX1 in PanNET

Introduction: Previously, we identified CUX1 as mediator of metastatic behaviour and poor differentiation in human insulinomas. CUX1 mediated tumor-promoting functions via enhancing proliferation, resistance to apoptosis and angiogenesis in-vitro and in-vivo.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Weißbach J

Authors: Weißbach J, Schmitz R, Haybäck J, Perren A, Blank A,

Keywords: CUX1, RIP1Tag2, DAPK1, Apoptosis, Tumor Progression,

#1488 Chemoprevention with a Long Acting Somatostatin Analogue in a Multiple Endocrine Neoplasia Type 1 (MEN1) Knockout Mouse Model Does Delay the Progression of Pancreatic Neuroendocrine Neoplasms (pNENs)

Introduction: Long acting somatostatin analogues (LAR) are an essential part of the treatment of neuroendocrine tumours.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Lopez C

Authors: Lopez C, Bartsch D, Albers M, Bollmann C, Roth S,

Keywords: chemoprevention, neuroendocrine neoplasms, somatostatin analogue ,